Annual report pursuant to Section 13 and 15(d)

Licensing and Other Arrangements - Takeda (Details)

v3.24.0.1
Licensing and Other Arrangements - Takeda (Details) - USD ($)
$ in Thousands
 1 Months Ended 12 Months Ended 38 Months Ended
Nov. 01, 2006
Nov. 30, 2020
Feb. 28, 2009
Dec. 31, 2023
Dec. 31, 2022
Dec. 31, 2023
Licensing and other arrangements            
Revenue from contracts with customers       $ 2,650 $ 4,150  
Takeda Pharmaceutical Company Limited | Collaboration Agreement            
Licensing and other arrangements            
Maximum eligible milestone payments receivable       16,000   $ 16,000
Revenue from contracts with customers           3,000
Contract assets       0 0 0
Contract liabilities       0 0 0
Capitalized contract costs       0 0 $ 0
Takeda Pharmaceutical Company Limited | Collaboration Agreement | TAK-079 and TAK-169            
Licensing and other arrangements            
Maximum eligible milestone payments receivable $ 19,000          
Minimum period eligible to receive royalties 13 years 6 months          
Royalty payment period from the first commercial sale of each royalty-bearing discovery product 12 years          
Takeda Pharmaceutical Company Limited | Collaboration Agreement | Other antibodies            
Licensing and other arrangements            
Maximum eligible milestone payments receivable per discovery product candidate     $ 3,300      
Minimum period eligible to receive royalties     10 years      
Takeda Pharmaceutical Company Limited | Collaboration Agreement | Milestone            
Licensing and other arrangements            
Revenue from contracts with customers   $ 2,000   0 800  
Takeda Pharmaceutical Company Limited | Collaboration Agreement | License            
Licensing and other arrangements            
Revenue from contracts with customers       $ 100 $ 100